HUTCHMED Switches Clinical Strategy To Rely On Partnerships For Late-Stage Assets In US

 
• By Dexter Jie Yan
  
Generate a summary of this article
Listen to this article
Beta

Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.

Asia strategy
HUTCHMED seeks partnerships to advance three molecules into the clinic outside of China. • Source: Shutterstock

Aiming to become profitable in 2025, HUTCHMED (China) Limited is likely to move away from running costly late-stage international clinical trials by itself, primarily in the US, and is instead seeking partnerships to advance three molecules into the clinic outside of China, company executives said during the group's R&D Day on 9 July.

Key Takeaways

  • HUTCHMED has initiated China-only Phase III or II/III clinical trials with three molecules, namely IDH 1 and IDH 2 dual inhibitor HMPL-306, Syk inhibitor sovleplenib and VEGFR/FGFR inhibitor surufatinib.

The new approach is mostly pronounced in the clinical development of its isocitrate dehydrogenase (IDH) 1 and IDH 2 dual...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

Embracing China’s Brave New Pharmaceutical World!

 
• By Ellon Xu, Philip Leung, and Grace Shieh

Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.